1. South Korea Stocks

  2. •

    Health technology

  3. •

    Medical specialties
L&C BIO Co., Ltd.

L&C BIO Co., Ltd.

KKRX:290650
59,700.00
KRW
-4,600.00
(-7.15%)
-5,623.13EPS
1.60TMarket Cap
Nov 18Next Earn
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
1,190.33
1,541.51
2,238.56
1,128.46
1,331.02
1,505.87
2,050.01
2,313.84
2,906.39
3,175.42
3,594.13
4,078.99
Basic EPS, GAAP
159
258.33
469.33
276.67
331.03
493.83
620
200
2,132
6,242
-5,810
-5,619.28
Free Cash Flow per Basic Share
-212.14
-117.51
440.11
-48.99
201.9
199.32
-23.39
-1,926.82
-1,636.3
-613.47
-187.99
-149.32
Dividend per Share
- -
- -
- -
- -
- -
33.31
48.37
49.07
49.15
100
47.2
0.03
Book Value per Share
210.23
538.32
903.29
2,417.3
2,635.36
2,642.34
3,747.89
4,317.94
6,477.65
12,382.77
8,151.79
8,240.47
Tangible Book Value per Share
208.14
532.44
898.3
2,413.31
2,625.46
2,632.5
3,697.2
4,160.33
6,413.47
3,599.89
2,896.33
3,052.63
Basic Weighted Avg Shares
8
8
8
19
22
22
22
23
23
23
24
24
Sales/Revenue/Turnover
8,999
11,822
17,901
21,241
29,152
32,973
45,677
52,572
65,927
72,032
85,476
98,100
Operating Margin (%)
12.48
17.54
27.21
25.79
30.98
22.21
28.83
18.04
12.33
5.37
5.17
10.81
Depreciation Expense
233
287
295
482
1,086
1,587
2,902
4,508
5,654
6,754
8,234
8,416
Net Income, GAAP
1,202
1,981
3,753
5,208
7,250
10,813
13,814
4,544
48,361
141,596
-138,175
-135,144
Effective Tax Rate (%)
6.06
10.28
18.64
13.52
14.79
6.15
8.86
- -
22.77
- -
- -
- -
Profit Margin (%)
13.36
16.76
20.97
24.52
24.87
32.79
30.24
8.64
73.36
196.57
-161.65
-137.76
Working Capital
5,154
11,406
14,770
46,846
42,689
41,826
41,998
45,546
28,519
-24,519
-98,607
-88,745
LT Debt
943
401
- -
1,000
1,622
14,663
6,098
71,303
1,417
24,038
8,247
4,006
Total Equity
3,913
10,020
16,813
52,799
60,271
61,253
93,265
107,821
156,856
291,274
208,533
213,217
Return on Invested Capital (%)
- -
22.19
27.8
13.31
13.32
10.08
13.82
- -
2.86
- -
- -
- -
Return on Capital (%)
- -
27.29
28.42
15.02
10.53
14.71
14.14
- -
24.7
- -
- -
- -
Return on Common Equity (%)
- -
28.44
27.97
15.03
13.1
18.64
19.34
4.97
39.5
66.19
-57.68
-55.6

Capital Structure

KRW

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
75,672
83,953
83,488
LT Borrowings
18,658
4,020
4,006
LT Finance Leases
- -
4,226
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
24
24
25
Market Capitalization
1,269,829
1,436,788
1,601,991

Working Capital

KRW

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
142,963
139,188
155,025
Cash, Cash Equivalents & STI
41,737
36,821
48,638
Accounts Receivable, Net
23,176
24,724
28,240
Inventories
45,621
42,817
41,661
Total Current Liabilities
205,432
237,795
243,770
Payables & Accruals
- -
- -
- -
ST Debt
75,672
83,953
83,488
Deferred Revenue
- -
- -
- -

Growth Rates

KRW

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
62.43%
34.13%
-28.41%
Free Cash Flow
680.16%
1,608.6%
-67.87%
Net Income, GAAP
120.15%
184.02%
-197.58%
Sales/Revenue/Turnover
25.88%
21.39%
18.66%
Total Cash Common Dividend
- -
- -
-50.52%

Quarterly Revenue

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
16,531
17,838
18,541
19,087
72,032
2025
17,671
20,581
22,556
24,668
85,476
2026
30,295
- -
- -
- -
- -

Quarterly Earnings Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
69
47
-227
6,122.43
6,242
2025
-18
-580.49
-2,288.69
-2,877.18
-5,810
2026
104.77
- -
- -
- -
- -

Quarterly Dividends Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
100
2025
- -
- -
- -
0.02
47.2
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Chul Lee Whan
Full Time Employees
155
Sector
Health technology
Industry
Medical specialties
Address
Suntechcity Seongnam GY South Korea 13229
IPO Date
Nov 1, 2018
Website
lncbio.co.kr
Similar Companies
Intuitive Surgical, Inc. (NASDAQ:ISRG)
Boston Scientific Corporation (NYSE:BSX)
Thermo Fisher Scientific Inc (NYSE:TMO)
Illumina, Inc. (NASDAQ:ILMN)
Abbott Laboratories (NYSE:ABT)
GRAIL, Inc. (NASDAQ:GRAL)
Business
L&C Bio Co., Ltd. develops and commercializes regenerative medicine products focused on tissue engineering, including human tissue grafts, allograft-based medical devices, pharmaceuticals, functional cosmetics, and health functional foods. The company offers core products such as MegaDerm, an acellular dermal matrix for burns, reconstructions, and tympanoplasties; MegaNerve and MegaNerve Prime, ready-to-use nerve allografts for nerve reconstruction; MegaCarti, a cartilage allograft for orthopedic applications; xenografts utilizing horse cartilage; Ritwo, a popular skin booster; Re2O, a leading K-medical tourism procedure launched within the past year; and additional lines like Phion 2.0 imaging devices, CBCT systems, and cosmeceuticals for skin repair, renewal, and remodeling. L&C Bio operates primarily in South Korea with exports to other regions and maintains facilities including its headquarters and human tissue plant in Seongnam-si, Gyeonggi-do; a pharmaceutical plant in Anseong-si; and offices in Seoul and Busan. Founded in 2011 and headquartered in Seongnam-si, South Korea, the company, recognized as Asia's largest skin and soft tissue bank, primarily serves healthcare professionals, hospitals, and the medical tourism sector through patented processing technologies like AlloClean. In recent developments, L&C Bio secured the world's first NMPA approval in China for MegaDerm Plus in January 2025, enabling full-scale market entry in the first half of 2025 amid local supply shortages; completed the acquisition of full ownership in L&C China using internal funds to strengthen strategic control and distribution without issuing convertible bonds; announced plans in late 2024 to acquire L&C Bioscience Technology (Kunshan) Co., Ltd. for KRW 55.4 billion; launched MegaNerve Prime nerve allograft by late 2023; and introduced Re2O, which rapidly gained prominence in K-medical tourism by December 2025.